An Overview of Pharmaceutical Co-Crystal
DOI:
https://doi.org/10.22270/ajprd.v7i2.483Keywords:
Pharmaceutical co-crystal, Co-crystallization, coformers, Hydrogen bonding.Abstract
Pharmaceutical co-crystals are nonionic supramolecular complexes and supramolecular chemistry. Pharmaceutical co-crystal consists of active pharmaceutical ingredients and coformers. Pharmaceutical co-crystals can be employed to improve vital physicochemical characteristics of a drug, including solubility, dissolution, bioavailability and stability of pharmaceutical compounds while maintaining its therapeutic activity. Co-crystals can be constructed through several types of interaction, including hydrogen bonding, pi-stacking, and vander Waals forces. Pharmaceutical co-crystals could play a major role in the future of API formulation. Pharmaceutical co-crystal can be improvement future aspect problems related physicochemical properties of API
Downloads
References
2. Hisada N, Takano R, Takata N, Shiraki K, Ueto T, Tanida S, et al. Characterizing the dissolution profile of supersaturable salts, co-crystal and solvates to enhance in vivo oral absorption. Eur J Pharm Biopharm 2016; 103:192-9.
3. Savjani KT, Gajjar AK, Savjani JK. Drug solubility: Importance and enhancement techniques. ISRN Pharm 2012; 195727.
4. Desiraju GR. Crystal engineering: a holistic view. Angew Chem Int Ed Engl 2007; 46(44):8342-56.
5. Etter MC. Encoding and decoding hydrogen-bond patterns of organic compounds. Acc Chem Res 1990; 23:120-6.
6. Etter MC. Hydrogen bonds as design elements in organic chemistry. J Phys Chem 1991; 95 4601-10.
7. Zaworotko M. Crystal Engineering of Co-crystals and their Relevance to Pharmaceuticals and Solid-State Chemistry. Acta Cryst 2008; A64:C11-C12.
8. Rodríguez-Hornedo N, Nehm SJ, Jayasankar A, Co-crystal: Design, Properties and Formation Mechanisms, In Encyclopedia of Pharmaceutical Technology, 3rd Edition, Taylor & Francis, London, 2007; 615-635.
9. Schultheiss N, Newman A, Pharmaceutical Co-crystals and their Physicochemical Properties. Cryst Growth Des, 2009; 9:2950–2967.
10. Tiekink ERT, Vittal JJ, Frontiers in Crystal Engineering, John Wiley & Sons, Ltd, 2006; Chapter 2: Crystal Engineering of Pharmaceutical Co-crystals, pp 25-50.
11. Vishweshwar P, McMahon JA, Bis JA, Zaworotko MJ, Pharmaceutical Co-crystals J Pharm Sci 2006; 95:499-516.
12. Remenar JF, Morissette SL, Peterson ML, Moulton B, MacPhee JM, Guzmán H, Almarsson O, Crystal Engineering of Novel Co-crystals of A Triazole Drug With 1,4-Dicarboxylic Acids, J Am Chem Soc, 2003; 125:8456-8457.
13. Almarsson Ö, Zaworotko MJ. Crystal Engineering of the Composition of Pharmaceutical Phases. Do Pharmaceutical Co-crystals Represent A New Path To Improved Medicines Chem Commun 2004; 1889-1896.
14. Peterson ML, Hickey MB, Zaworotko MJ, Almarsson O, Expanding the Scope of Crystal Form Evaluation in Pharmaceutical Science. J Pharm Pharmaceut Sci 2006; 9(3):317-326
15. Fleischman SG, Kuduva SS,McMahon JA,Moulton B,Walsh RB, Rodriguez-Hornedo N, Zaworotko MJ, Crystal Engineering of the Composition of Pharmaceutical Phases, Cryst Growth Des 2003; 3:909-919.
16. McNamara DP, Childs SL, Giordano J, Iarriccio A, Cassidy J, Shet MS, Mannion R, O'Donnell E, Park A. Use of A Glutaric Acid Co-crystal to Improve Oral Bioavailability of A Low Solubility API. Pharma Res ,2006; 23:1888-1897.
17. Vishweshwar P, McMahon JA, Peterson ML, Hickey MB,Shattock TR, Zaworotko MJ. Crystal Engineering of Pharmaceutical Co-crystals from Polymorphic Active Pharmaceuti-Cal Ingredients. Chem Commun.2005; 4601-4603.
18. Babu NJ, Reddy LS, Aitipamula S, Nangia A, Polymorphs and Olymorphic Co-crystal of Temozolomide. Chem Asian J 2008; 3:1122-1133.
19. Sarma B, Reddy LS, Nangia A. The Role of Π-Stacking In the Composition of Phloroglucinol and Phenazine Co-crystal, Cryst Growth Des 2008; 8:4546-4552.
20. Abourahma H, Cocuzza DS, Melendez J, Urban JM, Pyrazinamide Co-crystal and the Search for Polymorphs. Cryst Eng Comm 2011; 13:1-22.
21. Batisai E, Ayamine A, Kilinkissa OEY, Bathori N. Melting Point-Solubility-Structure Correlations In Multicomponent Crystal Containing Fumaric Or Adipic Acid. Cryst Eng Comm 2014; 16:9992-8.
22. Stanton MK, Bak A. Physicochemical Properties of Pharmaceutical Co crystal: A Case Study Of Ten AMG 517 Co crystal. Cryst Growth Des 2008; 8:3856-62.
23. Aakeroy CB, Forbes S, Desper J. Using Co-crystal to Systematically Modulate Aqueous Solubility and Melting Behaviour of an Anticancer Drug. J Am Chem Soc 2009; 131:17048-9.
24. Fleischman SG, Kuduva SS, McMahon JA, Moulton B, Walsh B, Rodriguez-Hornedo RD, et al. Crystal Engineering of The Composition of Pharmaceutical Phases: Multiple-Component Crystalline Solids Involving Carbamazepine. Cryst Growth Des 2003:3; 909-19.
25. Stanton, Bak MK, A. Physicochemical Properties of Pharmaceutical Co-crystals: A Case Study of Ten AMG Co-crystals. Cryst. Growth Des. 2008; 8:3856–3862.
26. Stanton MK, Tufekcic S, Morgan C. Bak A, Drug Substance and Former Structure Property Relationships in 15 Diverse Pharmaceutical Co-crystals. Cryst. Growth Des. 2009; 9:1344–1352.
27. Jain A, Yang G, Yalkowsky S, H Ind Eng Chem Res 2004; 43:7618–7621.
28. Burger A, Ramberger R, Mikrochim. Acta 1979; 259–271.
29. Abramowitz R, Yalkowsky SH, Pharm Res, 1990; 7:942–947.
30. Jain N, Yalkowsky S H, J Pharm Res, 2001; 90:234–252
Published
How to Cite
Issue
Section
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.